In up to 5% of patients, CLL transforms from an indolent subtype to an aggressive form of B cell lymphoma (Richter's syndrome), which is associated with worse disease outcome and severe downregulation of NFAT2. This evidence concerns the gene NFATC1 and B-cell non-Hodgkin lymphoma.